KM 23

Drug Profile

KM 23

Alternative Names: KM 023

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Kainos Medicines
  • Developer Kainos Medicines; Unknown
  • Class
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 20 Jan 2017 Phase-II clinical trials in HIV infections (PO) (Kainos Medicine website, January 2017)
  • 07 Mar 2016 Phase I development is ongoing in South Korea
  • 07 Mar 2016 KM 23 is available for licensing as of 07 Mar 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top